The natural history of malignancies under conditions of BRAF inhibitor stimulation

Expert Opinion on Investigational Drugs

Volumn 20, Issue 1, 2011, Pages 135-136

  White, Robert M ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; PLX 4032; RAF PROTEIN; RAS PROTEIN;

CANCER RISK; CELL PROLIFERATION; DISEASE COURSE; DRUG MECHANISM; ENZYME INHIBITION; LETTER; MELANOMA; METASTASIS; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; HUMANS; INDOLES; MELANOMA; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; RISK FACTORS; SKIN NEOPLASMS; SULFONAMIDES;

EID: 78650285898     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2011.542325     Document Type: Letter

References (5)

1. Livingstone E, Zimmer L, Piel S, Schadendorf D. PLX4032: does it keep its promise for metastatic melanoma treatment Expert Opin Investig Drugs 2010;19(11):1439-49
2. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010;464:431-5
3. Poulikakos PI, Zhang C, Bollag G, et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464:427-30
4. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19
5. Goydos JS, Mann B, Kim HJ, et al. Detection of B-RAF and N-RAS mutations in human melanoma. J Am Coll Surg 2005;200:362-70